Why Curaleaf Holdings Stock Popped by Almost 25% on Tuesday

President Trump told reporters he is “considering” using an executive order to direct the Justice Department and DEA to begin rescheduling marijuana from Schedule I — his strongest signal yet toward federal cannabis reform — and marijuana stocks jumped on the news, with Curaleaf rising about 25%. Rescheduling would effectively relax federal prohibitions, potentially unlocking banking, financing and a nationwide market for cannabis operators and materially improving their access to capital. Trump stopped short of confirming the order, however, so timing and implementation remain uncertain, but the prospect alone has re‑rated sector valuations and raises the stakes for policy and industry outcomes.

Analysis

President Trump told reporters he is "considering it, yeah" and that he and his team are "looking at that very strongly" on using an executive order to direct the Justice Department and DEA to begin rescheduling marijuana, his strongest public signal to date. The immediate market reaction was pronounced: marijuana stocks rallied on the speculation and Curaleaf Holdings (OTC: CURLF) advanced by almost 25% intraday as investors priced in a policy shift.

Rescheduling marijuana out of Schedule I — a change the article equates with de facto legalization — would remove major federal hurdles cited by operators, notably lack of access to basic banking and financial products, and could create a nationwide market that materially improves access to capital for multi-state operators. The piece frames that regulatory change as the primary catalyst that would transform sector economics and ease current liquidity and financing constraints.

Material uncertainty remains because the President stopped short of confirming an order and formal action requires DOJ/DEA process and timing that the article does not specify. The rally represents a policy-driven rerating rather than new company fundamentals; the Motley Fool note that Curaleaf was not among its Stock Advisor top 10 underscores the need for selective stock-level diligence even as sector sentiment turns mildly positive.

Key Decisions for Investors

• Trim or size new positions in cannabis names after the 25% pop in Curaleaf and treat recent gains as policy-driven until a formal EO or DEA action is documented
• Monitor concrete catalysts closely — issuance of an executive order, DOJ/DEA rescheduling notices, and explicit banking/regulatory guidance — and only increase exposure after those milestones or clear implementation timelines
• Prioritize operators with stronger balance sheets and proven state-market footprints that would most quickly monetize broader banking and capital access, and avoid companies that are capital constrained
• Use hedges or limit position sizes to manage event-risk given the speculative rerating and absence of confirmed federal action